Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: December 9, 2005
Last updated: April 14, 2015
Last verified: April 2015
Pharmacokinetic (PK) study to characterize changes in serum concentrations in epilepsy patients when switching from LAMICTAL immediate-release to extended-release and vice versa.

Condition Intervention Phase
Drug: lamotrigine extended-release
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Primary Purpose: Treatment
Official Title: An Open-label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine When Switching Patients With Epilepsy on LAMICTAL Immediate-release to Extended-release Formulation and Vice Versa

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Steady state AUC(0-24), Cmax and Ct (approximate Cmin) of lamotrigine

Secondary Outcome Measures:
  • Tmax and fluctuation index of lamotrigine
  • Adverse events, changes in blood pressure and heart rate
  • Change in seizure frequency during each of the study phases
  • Subject preference at End of Baseline and Extended-Release Treatment Phases

Estimated Enrollment: 45
Study Start Date: October 2005
Study Completion Date: June 2006
Primary Completion Date: June 2006 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   13 Years and older   (Child, Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Confident diagnosis of epilepsy.
  • Currently on LAMICTAL and up to 2 concomitant AEDs (anti-epileptic drugs).

Exclusion Criteria:

  • Females of childbearing potential cannot be on hormonal contraceptives or hormone replacement therapy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00264615

United States, Alabama
GSK Investigational Site
Anniston, Alabama, United States, 36207
United States, Arizona
GSK Investigational Site
Sun City, Arizona, United States, 85351
United States, Kentucky
GSK Investigational Site
Lexington, Kentucky, United States, 40503
GSK Investigational Site
Lexington, Kentucky, United States, 40536-0284
United States, Massachusetts
GSK Investigational Site
Boston, Massachusetts, United States, 02215
United States, Ohio
GSK Investigational Site
Toledo, Ohio, United States, 43614-5809
United States, Texas
GSK Investigational Site
Dallas, Texas, United States, 75230
United States, Virginia
GSK Investigational Site
Richmond, Virginia, United States, 23219
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: GlaxoSmithKline Identifier: NCT00264615     History of Changes
Other Study ID Numbers: LEP103944 
Study First Received: December 9, 2005
Last Updated: April 14, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
once daily dosing

Additional relevant MeSH terms:
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers processed this record on August 25, 2016